FREEDOM-DM1: Final Results from a Phase 1, Placebo-controlled SAD Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)
Development of PGN-EDODM1, a Novel Enhanced Delivery Oligonucleotide that Targets the Root Cause of Myotonic Dystrophy Type 1
